Above average or high BMI—often linked to cancers, diabetes, cardiovascular and other diseases—may in some cases improve the chance of survival among certain cancers, new research from Flinders University indicates.
Focusing on clinical trials of atezolizumab, a common immunotherapy treatment for non-small-cell lung cancer (NSCLC), the Australian cancer researchers found improved responsiveness to the drug in those with a high body mass index (BMI).
Ccopd and high blood pressure
Lung Cancer Treatment
COPD and Radiation for Breast Cancer
